INCR Stock Chart & Stats
$5.68
-$0.06(-6.52%)
At close: 4:00 PM EDT
$5.68
-$0.06(-6.52%)
Day’s Range― - ―
52-Week Range$3.40 - $7.60
Previous Close$0.94
Volume14.51K
Average Volume (3M)4.32K
Market Cap
$53.78M
Enterprise Value$309.28M
Total Cash (Recent Filing)$46.67M
Total Debt (Recent Filing)$183.01M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
May 06, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.55
Shares Outstanding11,845,711
10 Day Avg. Volume4,970
30 Day Avg. Volume4,317
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.46
Price to Sales (P/S)0.68
P/FCF Ratio13.83
Enterprise Value/Market Cap5.75
Enterprise Value/Revenue1.14
Enterprise Value/Gross Profit7.60
Enterprise Value/Ebitda-6.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryRevenue growth returning after two years of declines indicates that demand and sales execution recovered in 2025. If maintained, the 11.1% rebound can support greater scale across the company’s medical-cannabis channels and provide a stronger base for rebuilding earnings.
Improved Cash GenerationPositive operating and free cash flow in 2025 marks a meaningful improvement in internal cash generation after large outflows in 2023–2024. Continued conversion of operations into cash would give InterCure more capacity to fund activity and reduce reliance on external financing.
Integrated Value ChainOperating across cultivation, manufacturing, distribution and pharmacies lets InterCure participate in multiple stages of the medical-cannabis value chain. This integrated footprint, including company-operated dispensing channels, can support product availability and direct access to patients in Israel.
Bears Say
Persistent UnprofitabilityDespite the revenue rebound and narrower losses, InterCure remained loss-making through 2025, with a -13.2% net margin. Persistent unprofitability limits retained funding for growth and shows that improved sales have not yet translated into a durable earnings engine.
Negative Return On EquityNegative ROE for three consecutive years shows that the sizable equity base has not generated profits. If this pattern persists, capital efficiency will remain weak and continued losses could gradually reduce the balance sheet’s resilience despite currently manageable leverage.
Cash Flow VolatilityThe 2025 cash-flow rebound is not yet proven durable because operating and free cash flow were meaningfully negative in both 2023 and 2024. Such volatility makes internally generated funding less predictable and complicates planning for investment, operations, and balance-sheet protection.
Intercure News
INCR FAQ
What was InterCure’s price range in the past 12 months?
InterCure lowest stock price was $3.40 and its highest was $7.60 in the past 12 months.
What is InterCure’s market cap?
InterCure’s market cap is $53.78M.
When is InterCure’s upcoming earnings report date?
InterCure’s upcoming earnings report date is May 06, 2027 which is in 192 days.
How were InterCure’s earnings last quarter?
InterCure released its earnings results on Feb 19, 2026. The company reported -$1.047 earnings per share for the quarter.
Is InterCure overvalued?
According to Wall Street analysts InterCure’s price is currently Overvalued.
Does InterCure pay dividends?
InterCure does not currently pay dividends.
What is InterCure’s EPS estimate?
InterCure’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InterCure have?
InterCure has 11,845,711 shares outstanding.
What happened to InterCure’s price movement after its last earnings report?
InterCure reported an EPS of -$1.047 in its last earnings report. Following the earnings report the stock price went down -4.263%.
Which hedge fund is a major shareholder of InterCure?
Currently, no hedge funds are holding shares in INCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InterCure
InterCure Ltd., alongside its affiliated companies, is actively involved in the medical cannabis industry, operating both domestically in Israel and internationally. Their activities encompass the entire spectrum from research and cultivation to production, marketing, and distribution of medical cannabis products. The company's product line features dried cannabis flowers and an oil-based cannabis extract. Additionally, InterCure allocates investments to the biomedical sector. Established in 1994, the firm's main headquarters are situated in Herzliya, Israel.
Technical Analysis
Ownership Overview
―
Insiders
0.19% Mutual Funds
― Other Institutional Investors
98.38% Public Companies and
Individual Investors